S. Tejpar

Publications428
h-index73
Citations31,965
Highly Influential Citations1,385
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • E. Van Cutsem
  • 851 Publications • 96,135 Citations
  • J. Tabernero
  • 1,104 Publications • 55,987 Citations
  • S. Siena
  • 680 Publications • 52,846 Citations
  • P. Laurent-Puig
  • 714 Publications • 51,100 Citations
  • Publications
  • Influence
The Consensus Molecular Subtypes of Colorectal Cancer
TLDR
An international consortium dedicated to large-scale data sharing and analytics across expert groups is formed, showing marked interconnectivity between six independent classification systems coalescing into four consensus molecular subtypes (CMSs) with distinguishing features.
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
TLDR
First-line treatment with cetuximab plus FOLFIRI, as compared with F OLFIRI alone, reduced the risk of progression of metastatic colorectal cancer and was limited to patients with KRAS wild-type tumors.
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
TLDR
These ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
TLDR
The addition of cetuximab to FOLFIRI as first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of disease progression and increase the chance of response in patients with KRAS wild-type disease.
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
TLDR
In stage II-III colon cancer, the KRAS mutation status does not have major prognostic value, but BRAF is prognostic for OS in MS-L/S tumors.
Guidelines for the clinical management of familial adenomatous polyposis (FAP)
TLDR
The guidelines described herein may be helpful in the appropriate management of FAP families and, in order to improve the care of these families further, prospective controlled studies should be undertaken.
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.
A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4)
Peutz–Jeghers syndrome: a systematic review and recommendations for management
TLDR
The proposed guidelines contained in this article have been produced as a consensus statement on behalf of a group of European experts who met in Mallorca in 2007 and who have produced guidelines on the clinical management of Lynch syndrome and familial adenomatous polyposis.
...
1
2
3
4
5
...